Study on the prevalence of facial lipoatrophy in patients infected by HIV virus receiving antiretroviral drugs - FRAN08-005 FRESH-PEF115-en Isabelle COHEN-CODAR Study on the prevalence of facial lipoatrophy in patients infected by HIV virus receiving antiretroviral drugs - FRAN08-005 PREFACE FRESH-PEF115-en 115 FRESH-PEF115 Isabelle COHEN-CODAR ABBOTT FRANCE Epidemiology France Portal (PEF) AGENCE NATIONALE DE RECHERCHES SUR LE SIDA ET LES HEPATITES VIRALES (ANRS MIE) REGION AUVERGNE RHONE ALPES null side-effects Infectious disease medicine Healthcare system determinants: Use of care Healthcare system determinants Describe the prevalence of the facial lipoatrophy in patients infected by HIV virus and receiving antiretroviral drugs. Describe the prevalence of lipoatrophies and lipodystrophic mixed syndromes. Evaluate the score of quality of life, using the patients multi-dimensional auto-questionnaire and specific ABCD "Assessment of Body Change and Distress". null France Individuals Patients population Male Female Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Patient infected by HIV virus, receiving antiretroviral drugs for at least 1 month and coming to consultation at his usual follow-up center, during the period of the study, obtaining of the written consent for the collect and exploitation of his personal data. Clinical data Participant-reported health data Biological data Health event/morbidity Health care consumption and services One-time cross-sectional study Other Through organizations (health services or institutions schools businesses etc.) [1000-10000[ individuals Self-administered questionnaire Observational Study Observational Study 2131 Completed study To be defined Access on specific project only